Testing a new method for liver stiffness measurement
Part of Digestive system clinical trials.
This study tests a new, non-invasive way to measure liver stiffness using a device called FibroScan. It aims to make liver checkups easier and more comfortable for people with liver disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a liver condition or are being evaluated for one.
- You are covered by French Social Security (health insurance).
- You do not have fluid in your belly (ascites).
- You do not have heart failure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new way to use a FibroScan (a non-invasive liver scanner) with a single probe to measure liver health in people with chronic liver disease. If you have a long-term liver condition, this trial may help improve how liver exams are done.
This study tests a new wearable patch that uses ultrasound to measure liver stiffness without needing a permanent probe. It could be a more comfortable and convenient way to check your liver health, and results will be compared to the standard FibroScan test.
This study uses a special ultrasound during an endoscopic procedure to measure liver stiffness and fat, and compares it to a standard FibroScan. It aims to see if the new method works as well for people with normal liver health.
This study compares two non-invasive ultrasound methods (EUS-SWQ and FibroScan) with liver biopsy to see how well they detect liver scarring in patients with chronic liver disease. The goal is to improve how doctors diagnose and monitor liver damage from conditions like hepatitis B and fatty liver disease.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
This study looks at whether a city-hospital partnership can help find liver fibrosis (early scarring of the liver) earlier in people who get a Fibroscan test ordered by their primary care doctor. It is for adults whose Fibroscan result was at least 8 kPa and who had the test between 2023 and 2026.
Hear when a new Liver Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.